PMH9 COST-EFFECTIVENESS OF CLINICALLY PROVEN TREATMENT STRATEGIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN FIVE JURISDICTIONS
University of Wuerzburg, Aschaffenburg, Germany, 7 National Institutes of Mental Health, Bethesda, MD, USA ADHD is a common disorder of childhood and adolescence in the US and Europe. The NIMH MTA Study is a clinical landmark trial, including 579 children age 7-9.9 years with ADHD according to DSM-IV criteria, who were randomly assigned to 14 months of medication management (MedMgt), intense behavioral treatment (Beh), both combined (Comb), or community care (CC). OBJECTIVE: To evaluate the cost-effectiveness of clinically proven treatment strategies (neither placebo nor single drugs) for ADHD and Hyperkinetic Disorder (HKD/HKCD, a subgroup meeting ICD-10-based diagnostic criteria used in Europe) in five countries, using patient-level data from the MTA Study over 14 months. METHODS: Medical resource utilization data came from the MTA, excluding its research component. Unit costs (year 2005) were calculated from a societal and from a third-party payer's perspective for Germany, The Netherlands, Sweden, UK, and USA. Corresponding to the primary study endpoint, treatment response was defined as normalization of core symptoms (SNAP-IV teacher/parent scores <1). Utility estimates were derived from expert estimates and parent-proxy-ratings. RESULTS: Incremental cost-effectiveness ratios (ICERs) were determined for the total study population and subgroups with pure ADHD (without comorbidity, n = 184), pure HKD (n = 77), or HKD/HKCD (n = 145). ICERs per additional patient "normalized" ranged from to dominance to €4200 for MedMgt versus CC and from €21,000 to €100,000 for Comb versus MedMgt. MedMgt dominated Beh and exhibited extended dominance over CC compared to a hypothetical "Do Nothing" alternative. Results were supported by cost-effectiveness acceptability and sensitivity analyses. CONCLUSIONS: Despite international differences regarding standards of care, diagnostic criteria, and unit costs, key findings for European jurisdictions were consistent with US results. Although cost-utility estimates for this pediatric population should be interpreted with caution, results indicate acceptable to attractive cost-effectiveness of an intense MedMgt strategy. Further analyses will have to explore the impact of psychiatric comorbidity and broader clinical endpoints. University of Wuerzburg, Aschaffenburg, Germany, 7 National Institutes of Mental Health, Bethesda, MD, USA Beyond disease-defining core symptoms of inattention, hyperactivity, and impulsivity, ADHD is characterized by functional impairment of patients. The Columbia Impairment Scale (CIS) is a parent rating scale with relatively strong psychometric properties, tapping four major dimensions: interpersonal relations, psychopathology, schoolwork, and use of leisure time. OBJEC-TIVES: CIS ratings from the NIMH MTA Study (n = 579 children with ADHD according to DSM-IV-criteria) were used as an alternative outcome measure to evaluate the cost-effectiveness of medication management (MedMgt), intense behavioral treatment (Beh), both combined (Comb), or community care (CC) in the study population and in three subgroups: hyperkinetic disorder (according to ICD-10-criteria preferred in Europe); pure HKD or HKD/HKCD, and in pure ADHD, over 14 months. METHODS: For costing (societal and third-party payer's perspectives), patient-level resource utilization data were combined with country-specific unit costs for Germany, The Netherlands, Sweden, UK, and United States (year 2005). Incremental costeffectiveness ratios (ICERs) were determined using functional improvement (CIS effect size [ES], Cohen's d) as clinical outcome criterion. Four treatment strategies and a hypothetical "Do Nothing" alternative were compared with each other.
PMH10 FUNCTIONAL IMPAIRMENT OF PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN ALTERNATIVE COST-EFFECTIVENESS ANALYSIS OF CLINICALLY PROVEN TREATMENT STRATEGIES BASED UPON

RESULTS:
The four MTA treatment strategies were all clinically effective. Across jurisdictions, both CC versus "Do Nothing" (ICERs ranging from €1200/ES to €2600/ES) and MedMgt (ICERs versus "Do Nothing" from €1000/ES to €2700/ES, ICERs versus CC from dominance to €3000/ES) appeared attractive on grounds of cost-effectiveness. MedMgt dominated Beh, and ICERs for Comb versus MedMgt ranged from €500,000/ES to €1,000,000/ES. Results for subgroups with pure ADHD, HKD/HKCD, and pure HKD were broadly similar. Sensitivity analyses including probabilistic evaluations using non-parametric bootstrapping supported these findings. CONCLUSIONS: Despite notable international differences in terms of diagnostic criteria, standards of care, and unit costs, the cost-effectiveness of MTA-based clinical treatment strategies for patients with pure ADHD seemed remarkably similar across jurisdictions. The impact of comorbidity remains to be explored. 
PMH11 RATIONAL CHOICE OF TREATMENT STRATEGY IN MODERATE TO SEVERE ALZHEIMER'S DISEASE PATIENTS
